1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Bayer AG
  6. News
  7. Press Releases
    BAYN   DE000BAY0017

BAYER AG

(BAYN)
  Report
Real-time Estimate Tradegate  -  05/24 11:22:43 am EDT
63.40 EUR   -1.67%
05:21aBayer Commits To UN's Zero Hunger Private Sector Pledge
MT
05/23Bayer's Kerendia Found to Reduce Hospitalization for Heart Failure in Exploratory Post Hoc Study
MT
05/23BAYER : New data support renal and cardiovascular benefits of Kerendia™ (finerenone) in patients with and without history of left ventricular hypertrophy and chronic kidney disease and type 2 diabetes
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
Communiqués de presse de la société BAYER AG
05/23BAYER : New data support renal and cardiovascular benefits of Kerendia™ (finerenone)..
PU
05/23BAYER : Two large Xarelto™ studies support effectiveness of dual pathway inhibition ..
PU
04/29BAYER : “Bayer is on the right track”
PU
04/22BAYER : submits application in China for additional indication of darolutamide
PU
04/13BAYER : receives approval for precision oncology treatment Vitrakvi™ in China
PU
04/07Chinese man sentenced for stealing Monsanto trade secret
AQ
04/06BAYER : Early redemption / Cancellation / Delisting
PU
04/04BAYER : New data for finerenone on the risk reduction of cardiovascular and renal outcomes..
PU
04/04BAYER : XARENO study revealed Xarelto™ was associated with net clinical benefit and ..
PU
04/04BAYER : honors three young agricultural leaders with an award supporting the projects they..
PU
04/03BAYER : presents positive results from first Phase 2b trial on safety of asundexian in pat..
PU
04/01BAYER : set to drive breakthrough innovations in the Life Sciences
PU
03/31BAYER : to strengthen global Pharmaceuticals production network
PU
03/29Bayer receives approval in Japan for Kerendia (finerenone), a new treatment for adults ..
AQ
03/29BAYER : to present data from cardiovascular portfolio including late-breaking presentation..
PU
03/28BAYER : receives approval in Japan for Kerendia™ (finerenone), a new treatment for a..
PU
03/22BAYER : refinances 1.3 billion euro hybrid bond
PU
03/22Evotec receives EUR 3 m milestone payment for Bayer starting Phase II clinical developm..
AQ
03/16BAYER : 2021 Hansen Family Award goes to Professor Kai Johnsson
PU
03/16BAYER : submits application in the EU for an extension of the indication of finerenone to ..
PU
03/11BAYER : submits application for additional indication of Nubeqa™ (darolutamide) in J..
PU
03/09BAYER : submits applications in the U.S. and EU for additional indication of Nubeqa™..
PU
03/02BAYER : Rezultate financiare 2021 - transmis de SSIF TRADEVILLE SA
PU
03/01BAYER : Annual Report 2021 German (PDF, 3.09 MB)
PU
02/24BAYER : extends clinical development program for finerenone with Phase II study investigat..
PU
02/21BAYER : delivers on medical innovation fueling transformation of pharma business
PU
02/21BAYER : new treatment Kerendia® (finerenone) approved in EU for adult patients with chroni..
PU
02/16BAYER : highlights advancements of agriculture industry's most prolific R&D pipeline
PU
02/10BAYER : Receives U.S. FDA Fast Track Designation for asundexian Stroke Program
PU
02/09Bayer - AskBio and Touchlight Restructure Joint Venture
AQ
02/04BAYER : will discontinue phase II development candidate eliapixant
PU
01/19BlueRock Therapeutics Announces First Patient Dosed in Canada in Phase 1 Trial in Patie..
AQ
01/17BAYER : Annual Bayer Pharma Media Day 2022
PU
01/07Ex-Monsanto employee pleads guilty to corporate spying for China
AQ
01/07AVOIDING A TOXIC SITUATION : Lessons From Bard V. Monsanto
AQ
01/06Chinese man pleads guilty to stealing Monsanto trade secret
AQ
01/06Monsanto pleads guilty to pesticide-related crimes in Hawaii
AQ
01/03Hansa Biopharma enters into agreement with AskBio to evaluate feasibility of imlifidase..
AQ
2021Interim Report 2 (2021-08-01 - 2021-10-31)
AQ
2021BAYER : U.S. FDA approves Xarelto™ to treat venous thromboembolism (VTE) and to prev..
PU
2021BAYER : receives positive CHMP opinion for finerenone as a new treatment for adult patient..
PU
2021BAYER : Phase III trial with Nubeqa™ (darolutamide) in combination with docetaxel an..
PU
2021BAYER : Phase III trial with darolutamide in combination with docetaxel and androgen depri..
PU
2021Couple's $86M reward in Monsanto pesticide case stands
AQ
2021BAYER : extends clinical development program for finerenone with Phase III study in childr..
PU
2021New Phase III study to investigate expanded use of vericiguat in patients with chronic ..
PU
2021Bayer Submits Aflibercept for regulatory approval in the EU and Japan for Retinopathy o..
PU
2021Rodrigo Santos named member of the Board of Management, Bayer AG, and President of the ..
PU
2021Bayer grows sales and earnings significantly
PU
2021New data from finerenone clinical trial program reinforces renal and cardiovascular ben..
PU
2021Bayer to present data from cardiovascular portfolio, including analyses from the compre..
PU
2021European Patent Office maintained Bayer patent on the once-daily administration of riva..
PU
2021Bayer to present new data from comprehensive finerenone clinical trial program
PU
2021BAYER : Belmora Seeks SCOTUS Review For The Second Time In Its Cross-Border Trademark Batt..
AQ
2021BAYER : Gadovist™ (Gadobutrol) at a Reduced Dose Demonstrates Non-Inferiority Compar..
PU
2021BAYER : New data for rivaroxaban in patients following the Fontan procedure and at risk fo..
PU
2021BAYER : Middle East announces partnership with the United Nations Population Fund Egypt, t..
PU
2021BAYER : extends clinical development program for finerenone with Phase III study in patien..
PU
2021BAYER : launches transparency register for scientific collaborations with external partner..
PU
2021BAYER : Latest analyses of Vitrakvi (larotrectinib) reaffirm powerful efficacy and tolerab..
PU
2021BAYER : Andes Raises USD 15 Million in Series A Funding Co-Led by Leaps by Bayer and Caval..
BU
2021BAYER : to highlight expanded research from growing oncology portfolio at ESMO Congress 20..
PU
2021BAYER : Eliapixant significantly decreased cough frequency in Phase IIb trial in patients ..
PU
2021BAYER : starts Phase III clinical development program OASIS with Elinzanetant
PU
2021BAYER : New Data on Finerenone for the protection of patients with chronic kidney disease ..
AQ
2021BAYER : New Data on Finerenone for the protection of patients with chronic kidney disease ..
PU
2021BAYER : U.S. FDA approves expansion of the peripheral artery disease (PAD) indication for ..
PU
2021BAYER : to present data from cardiovascular portfolio, including late breaking data from P..
PU
2021BAYER : to present data from cardiovascular portfolio, including late breaking data from P..
PU
2021BAYER : Belmora Files Petition For Writ Of Cetiorari In Long-Running FLANAX Battle With Ba..
AQ
2021BAYER : strengthens-drug-discovery-platform-through-acquisition-of-Vividion-Therapeutics
AQ
2021BAYER : Half-Year Financial Report 2021 English (PDF, 582 KB)
PU
2021BAYER : Strong growth, guidance upgrade
PU
2021BAYER : strengthens drug discovery platform through acquisition of Vividion Therapeutics
PU
2021BAYER : investigational P2X3 antagonist meets primary efficacy endpoint and shows favorabl..
AQ
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BAYER AG